Literature DB >> 29304533

Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins.

Katja Vogt1, Shailaja Mahajan-Thakur1, Robert Wolf1, Susanne Bröderdorf1, Conny Vogel1, Andreas Böhm1, Christoph A Ritter2, Markus Gräler3, Stefan Oswald1, Andreas Greinacher4, Heyo K Kroemer1,5, Gabriele Jedlitschky1, Bernhard H Rauch1.   

Abstract

Sphingosine-1-phosphate (S1P) is a potent lipid mediator released from activated platelets by an adenosine triphosphate (ATP)-dependent export mechanism. A candidate transport protein is the multidrug resistance protein 4 (MRP4/ABCC4), an ATP-dependent transporter highly expressed in platelets. Furthermore, several statins are known to affect platelet functions and exhibit antithrombotic properties. This study determines the involvement of MRP4 in the transport of S1P and a possible interference by statins. Transport studies in membrane vesicles of Sf9 cells containing recombinant human MRP4 revealed that MRP4 mediates ATP-dependent transport of fluorescein- and tritium-labelled S1P. Also, ATP-dependent S1P transport in platelet membrane vesicles containing endogenous MRP4 was inhibited by the MRP inhibitor MK571 and the MRP4-selective compound Ceefourin-1. Confocal microscopy using fluorescein-labelled S1P as well as boron-dipyrromethene (BODIPY)-labelled sphingosine indicated association of S1P and MRP4 in human platelets. In MRP4-deficient mice, agonist-induced S1P secretion was reduced compared with matched wild-type C57Bl/6 mice and platelet S1P concentrations were lower. Fluvastatin and rosuvastatin interfered with MRP4 function inhibiting ATP-dependent cGMP (cyclic guanosine monophosphate) uptake into MRP4-containing vesicles, inhibited MRP4-mediated S1P transport in vitro and significantly attenuated endogenous S1P release from agonist-activated platelet ex vivo. These data suggest that release of S1P from platelets depends on MRP4 and statins can interfere with this transport process. Potentially, this may be relevant for the pleiotropic anti-inflammatory effects of statins and their effect on modulating atherothrombosis. Schattauer GmbH Stuttgart.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29304533     DOI: 10.1160/TH17-04-0291

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 2.  Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer.

Authors:  Hendrik Ungefroren; Frank Gieseler; Roland Kaufmann; Utz Settmacher; Hendrik Lehnert; Bernhard H Rauch
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

Review 3.  Sphingolipidomics in Translational Sepsis Research-Biomedical Considerations and Perspectives.

Authors:  Ralf A Claus; Markus H Graeler
Journal:  Front Med (Lausanne)       Date:  2021-01-20

Review 4.  Sphingolipids in Hematopoiesis: Exploring Their Role in Lineage Commitment.

Authors:  Yasharah Raza; Huda Salman; Chiara Luberto
Journal:  Cells       Date:  2021-09-22       Impact factor: 7.666

5.  Specific inhibition of the transporter MRP4/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets.

Authors:  Robert Wolf; Sophie Grammbauer; Raghavendra Palankar; Céline Tolksdorf; Eileen Moritz; Andreas Böhm; Mahmoud Hasan; Annika Hafkemeyer; Andreas Greinacher; Mladen V Tzvetkov; Bernhard H Rauch; Gabriele Jedlitschky
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

6.  Roles of ABCC1 and ABCC4 in Proliferation and Migration of Breast Cancer Cell Lines.

Authors:  Floren G Low; Kiran Shabir; James E Brown; Roslyn M Bill; Alice J Rothnie
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

7.  Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.

Authors:  Julian Friebel; Eileen Moritz; Marco Witkowski; Kai Jakobs; Elisabeth Strässler; Andrea Dörner; Daniel Steffens; Marianna Puccini; Stella Lammel; Rainer Glauben; Franziska Nowak; Nicolle Kränkel; Arash Haghikia; Verena Moos; Heinz-Peter Schutheiss; Stephan B Felix; Ulf Landmesser; Bernhard H Rauch; Ursula Rauch
Journal:  Cells       Date:  2021-12-13       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.